Selection of an ePROM
PROM, toxicity
ADVERSE EVENT
Active discussions between the model development team allowed to identify an ePROM of particular interest, to both clinicians and patients. The patient-representative mobilized her patient-advocacy network to collect and convey general perceptions on existing PROM, such as their perceived advantages and disadvantages to assess symptomatic ICI-related toxicity, via e-mail. The PRO version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE™) item library was considered comprehensive and suitably flexible, measuring a broad spectrum of symptoms [Patients participate in the IePRO trial for the first six months of their ICI treatment. Because the majority of IrAE occur within the first three to four months of treatment [